Compass Therapeutics Inc. (CMPX)
NASDAQ: CMPX
· Real-Time Price · USD
2.02
0.02 (1.00%)
At close: May 15, 2025, 1:33 PM
Company Description
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases.
The company's product candidates in the clinical stage of development include CTX-009, an investigational bispecific antibody that blocks Delta-like ligand 4/Notch and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137.
Its product candidates also comprise CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1.
The company was founded in 2014 and is headquartered in Boston, Massachusetts.
Compass Therapeutics Inc.
| Country | United States |
| IPO Date | Apr 5, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 35 |
| CEO | Dr. Thomas J. Schuetz M.D., Ph.D. |
Contact Details
Address: 80 Guest Street Boston, Massachusetts United States | |
| Website | https://www.compasstherapeutics.com |
Stock Details
| Ticker Symbol | CMPX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001738021 |
| CUSIP Number | 20454B104 |
| ISIN Number | US20454B1044 |
| Employer ID | 00-0000000 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Thomas J. Schuetz M.D., Ph.D. | Chief Executive Officer & Vice Chairman |
| Barry Shin J.D., M.B.A. | Chief Financial Officer |
| Anna Gifford | Communications Manager |
| Dr. James Kranz Ph.D. | Vice President and Head of Chemistry Manufacturing & Controls |
| Dr. Minori Rosales M.D., Ph.D. | Senior Vice President & Head of Clinical Development |
| Jonathan E. Anderman J.D. | Senior Vice President, General Counsel & Corporate Secretary |
| Karin Herrera B.A. | Senior Vice President & Head of Clinical Operations |
| Neil L. Lerner CPA | Senior Vice President & Chief Accounting Officer |
| Vered Bisker-Leib MBA, Ph.D. | Advisor |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 08, 2025 | 10-Q | Quarterly Report |
| May 08, 2025 | 8-K | Current Report |
| Apr 29, 2025 | DEFA14A | Filing |
| Apr 29, 2025 | ARS | Filing |
| Apr 29, 2025 | DEF 14A | Filing |
| Apr 11, 2025 | 4 | Filing |
| Apr 11, 2025 | 4 | Filing |
| Apr 11, 2025 | SCHEDULE 13D/A | [Amend] Filing |
| Apr 08, 2025 | 4 | Filing |
| Apr 08, 2025 | 4 | Filing |